Clinical trials targeting IGF1R in patients with advanced solid tumors have been described.[47, 48, 49, 50] While conflicting results were sometimes encountered, some patients exhibited profound responses to IGF1R inhibitor monotherapy, supporting the notion that IGF1R‐targeting is tumor and cellular/oncogenic context‐dependent. Here, IGF1R is linked to neoplasm.